The new product combines the proven benefits of the anti-inflammatory drug budesonide (Pulmicort®) with the rapid and long-acting bronchodilator formoterol (Oxis®) in a single inhaler to improve compliance and convenience for the patient.

"The use of these products in different combinations has shown outstanding asthma control when compared with the use of an anti-inflammatory compound alone. The new medication will provide patients with both rapid relief and long-term control of the disease," said Dr Colin Reddrop, Vice President & Head, Respiratory & Inflammation R&D. "This is a significant milestone for AstraZeneca's business in the respiratory area."

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products. AstraZeneca PLC is a major $15.8 billion international bioscience business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.